Aldo-Keto Reductase (AKR) 1C3 Inhibitors: A Patent Review
September 2017
in “
Expert opinion on therapeutic patents
”
Studysummary This review examines the patent literature on AKR1C3 inhibitors and suggests that although numerous potent inhibitors exist, further preclinical optimization is necessary before assessing their therapeutic potential in human diseases.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The review discussed the potential of Aldo-Keto Reductase (AKR) 1C3 inhibitors in treating various malignancies, including castration-resistant prostate cancer (CRPC), breast cancer, and acute myeloid leukemia (AML). It highlighted different classes of inhibitors, such as N-phenylsulfonylindoles and repurposed NSAIDs, and their mechanisms of action. Despite promising preclinical results, clinical trials like ASP9521 faced challenges such as lack of efficacy and drug resistance. The review emphasized the need for further optimization and suggested that precision medicine and combination therapies might be necessary to enhance the effectiveness of AKR1C3 inhibitors.
